What is the primary focus of the collaboration between Regeneron and Sanofi?

The primary focus of the collaboration is to discover, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (IO). This means both companies will work together on novel approaches to harnessing the immune system to fight cancer.

What financial benefits does Regeneron receive from this collaboration?

Regeneron receives substantial financial benefits, including a total upfront payment of $625 million. Additionally, Sanofi will reimburse Regeneron for a significant portion of the research and development costs, up to $825 million, for the discovery program. This provides substantial non-dilutive funding and reduces Regeneron's financial burden for early-stage research.

How are development and commercialization responsibilities structured under the collaboration?

The responsibilities are shared and can alternate. For candidates licensed by Sanofi, they will co-develop and co-commercialize. Sanofi will lead commercialization outside the U.S., while the U.S. commercialization lead will alternate on a candidate-by-candidate basis. Both parties can co-promote. Development costs are generally shared, with specific arrangements for reimbursement and profit sharing.

What is the significance of REGN2810 in this agreement?

REGN2810, Regeneron's antibody product candidate targeting PD-1, is a key asset in this collaboration. It will be co-developed with Sanofi, with shared development costs and equal profit sharing worldwide. Regeneron will lead U.S. commercialization, with Sanofi leading ex-U.S. commercialization. This indicates strong confidence in REGN2810's potential.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant strategic collaboration with Sanofi Biotechnology SAS focused on the discovery, development, and commercialization of antibody-based cancer treatments in the immuno-oncology (IO) field. This agreement includes two key components: an IO Discovery Agreement and an IO License and Collaboration Agreement. The collaboration is poised to significantly advance Regeneron's pipeline in a high-growth area of oncology. The financial terms are substantial, with Regeneron receiving a total upfront payment of $625 million ($265 million under the Discovery Agreement and $375 million under the License Agreement). Furthermore, Sanofi will reimburse a significant portion of Regeneron's research and development costs, up to $825 million for the IO Discovery Program, reducing Regeneron's upfront R&D expenditure. This partnership provides Regeneron with substantial non-dilutive funding and leverages Sanofi's extensive development and commercialization capabilities, positioning both companies for potential success in the competitive immuno-oncology market.

Key Highlights

1Regeneron and Sanofi entered into a global strategic collaboration to discover, develop, and commercialize antibody-based cancer treatments in immuno-oncology.
2Regeneron will receive a total upfront payment of $625 million from Sanofi.
3Sanofi will reimburse up to $825 million of Regeneron's costs for the IO Discovery Program, significantly de-risking early-stage research.
4The collaboration includes an IO Discovery Agreement, where Regeneron will identify and validate IO targets and develop antibodies through proof of concept, with a potential 5-year term extendable by Sanofi.
5The IO License and Collaboration Agreement allows Sanofi to license candidates from the discovery program, with joint development and commercialization responsibilities.
6Regeneron's lead immuno-oncology candidate, targeting PD-1 (REGN2810), will be co-developed with Sanofi, with shared development costs and equal profit sharing globally.
7A significant milestone payment of $375 million is available to Regeneron if sales of PD-1 targeting products and related combinations exceed $2 billion.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jul 31, 2015)

Summary

Key Highlights

Frequently Asked Questions